Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 21:00 source : Investor.aveooncology.com save search
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma
Published: 2022-10-12 (Crawled : 21:00) - investor.aveooncology.com
FNCTF | News | $11.0354 -0.83% -20.84% 0
|
Communications
|
| O: -4.1%
H: 0.0%
C: 0.0%
fotivda treatment patent application renal cell carcinoma
AVEO Oncology Reports Second Quarter 2022 Financial Results
Published: 2022-08-04 (Crawled : 21:00) - investor.aveooncology.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -1.08%
H: 0.94%
C: -0.38%
results
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
Published: 2022-07-28 (Crawled : 21:00) - investor.aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 0.14%
H: 1.38%
C: -1.24%
results
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
Published: 2021-07-08 (Crawled : 21:00) - investor.aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 0.52%
H: 5.66%
C: 5.15%
renal cell carcinoma
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
Published: 2021-05-19 (Crawled : 21:00) - investor.aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 2.2%
H: 3.16%
C: -0.14%
phase 2 positive results positive results
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
Published: 2021-05-19 (Crawled : 21:00) - investor.aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 2.2%
H: 3.16%
C: -0.14%
presentation renal phase 3 cell carcinoma
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
Published: 2021-05-10 (Crawled : 21:00) - investor.aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -3.98%
H: 14.59%
C: 9.78%
AZN | $68.36 -0.25% -0.25% 3.6M
|
Health Technology
|
| O: -1.93%
H: 1.6%
C: 1.44%
financial results results
AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update
Published: 2021-03-16 (Crawled : 21:00) - investor.aveooncology.com
HTGC F | $18.25 0.5% -0.27% 550K
|
Finance
|
| O: -0.18%
H: 0.22%
C: -0.62%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -4.82%
H: 6.08%
C: 2.39%
AZN | $68.36 -0.25% -0.25% 3.6M
|
Health Technology
|
| O: -0.5%
H: 0.64%
C: 0.54%
financial results results
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
UMAC | $1.55 0.65% 16.13% 3K
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
VLD 4 | $0.2638 -3.65% 13.27% 2.6M
|
Manufacturing
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
MGLD 4 | $1.13 5.61% 10.62% 200
|
Manufacturing
NURO | $3.65 2.24% 10.3% 3.9K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.